The effects of zinccorespTM tablets on patients with infections and respiratory disorders.
- Conditions
- Health Condition 1: J00-J99- Diseases of the respiratory system
- Registration Number
- CTRI/2024/02/063149
- Lead Sponsor
- apex laboratories private limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Age above 18 years of any gender.
2.Patients who are willing to give consent for the child’s participation in study.
3. Patients having recurrent episodes of any of the following
-Fever associated with respiratory tract infections (RTI)
- URTI (rhinitis, pharyngitis, laryngitis, influenza)-
LRTI (pneumonia, bronchitis, and bronchiolitis)
-Bronchial asthma
-COPD
-SARS-CoV-2
-Combined allergic rhinitis and asthma syndrome (CARAS)
-Pulmonary tuberculosis
1.Any evidence of malignancy.
2.History and clinical findings suggestive of metabolic diseases
3.History and clinical findings suggest chronic respiratory tract diseases including interstitial lung disease (ILD) and cystic fibrosis.
4.History of respiratory tract surgery.
5.Known diagnosis of congenital cardiac defects.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method